Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirine
Emma Rubenstein, Myriam Diemer, Lauriane Goldwirt, Caroline Lascoux‐Combe, Marie‐Laure Chaix, Agathe Rami, Diane Ponscarme, Matthieu Lafaurie, Blandine Denis, Nathalie De Castro, Julien Gras, Geoffroy Liégeon, Pierre‐Olivier Sellier, Laure Deville, Sylvie Chevret, Constance Delaugerre, Jean‐Michel Molina
Abstract
In a cohort of 72 consecutive virologically-suppressed patients with HIV-1 switching to long-acting cabotegravir and rilpivirine, we observed low cabotegravir trough concentrations 1 and 3 months after the first injection, with a significant association with no oral lead-in at 1 month [odds ratio (OR) = 6.3 [95% confidence interval (CI) 1.7-29.5], P = 0.01] and three months (OR = 5.6 [95% CI 1.3-29.7], P = 0.03), and with high BMI at 1 month (OR = 1.3 [95% CI 1.1-1.6], P = 0.007).